Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Fueling continuous innovation at BenevolentAI
BenevolentAI’s CTO, Daniel Neil, discusses the approaches we use to fuel continuous innovation in order to unlock new opportunities and future growth.
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
Please don’t use this sentence out of context
BenevolentAI and Stanford University review progress in their AI research partnership, which looks at the role of context in information extraction.
Contact us →
Company Registration: R.C.S. Luxembourg: B255412
Terms & Conditions
Privacy & Cookies Policy
WHAT WE DO
WORKING AT BENEVOLENT
FIND A JOB
NEWS & MEDIA